BloodCenter of Wisconsin (BCW) together with its consortium partner, the University of Wisconsin (UW) were awarded Core Clinical Center (CCC) status when the Transfusion Medicine and Hemostasis (TMH) Clinical Trial Network (CTN) began in 2002. Wisconsin TMH investigators have been active participants in Network activities over the initial 5 years of funding, helping to develop trials in several of the key areas being addressed by the Network and enrolling patients in the first approved Network study - """"""""Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients"""""""" or PLADO. This proposal is to continue our CCC's participation in the TMH-CTN over the next 5 years, helping to build on and implement additional clinical trials in these areas of medicine. Specifically, we propose to: 1) Continue our participation in the TMH-CTN trials that have been activated so far (PLADO, """"""""Study of Hemostasis and Invasive Procedures"""""""" (SHIP), and """"""""Rituximab for the treatment of Inhibitors in Congenital Hemophilia A"""""""" (RICH)) and to add to these, new trials as they are approved (e.g. """"""""Pipeline"""""""" trials: """"""""HIT Observational Thromboembolism Study"""""""" (HOT), """"""""Study of TTP and Rituximab: A Randomized Clinical Trial"""""""" (STAR) and """"""""High Dose Granulocyte Transfusions for the Treatment of Infections in Neutropenia"""""""" (the Granulocyte Trial)) and others as they are developed and approved. 2) Participate actively in the Network Steering Committee and Sub-Committee activities in proposing, developing and bringing to Network approval, additional relevant studies in the areas of hemostasis and transfusion medicine 3) Develop collaborative relationships and support training opportunities to facilitate the success of the proposed clinical trials and further the fields of transfusion medicine and hemostasis. 4) Together with TMH Colleagues, disseminate results of the TMH CTN through presentation and publication of clinical trial results and other TMH-CTN activities. Relevance: We believe that the trials developed to date all address important questions in transfusion medicine and hemostasis that required Network participation to be successful. This is in keeping with both the original RFA proposal and the stated objectives of the RFA for continuation of the TMH-CTN. ? ? ? BLOODCENTER OF WISCONSIN CRITIQUES ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01HL072290-06
Application #
7278876
Study Section
Special Emphasis Panel (ZHL1-CSR-J (M1))
Program Officer
Nemo, George J
Project Start
2002-09-30
Project End
2012-08-31
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
6
Fiscal Year
2007
Total Cost
$191,875
Indirect Cost
Name
Bloodcenter of Wisconsin, Inc.
Department
Type
DUNS #
057163172
City
Milwaukee
State
WI
Country
United States
Zip Code
53233
Uhl, Lynne; Assmann, Susan F; Hamza, Taye H et al. (2017) Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial. Blood 130:1247-1258
Price, Thomas H; Boeckh, Michael; Harrison, Ryan W et al. (2015) Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood 126:2153-61
Kaufman, Richard M; Assmann, Susan F; Triulzi, Darrell J et al. (2015) Transfusion-related adverse events in the Platelet Dose study. Transfusion 55:144-53
Leissinger, C; Josephson, C D; Granger, S et al. (2014) Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. Thromb Haemost 112:445-58
Triulzi, Darrell J; Assmann, Susan F; Strauss, Ronald G et al. (2012) The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 119:5553-62
Josephson, Cassandra D; Granger, Suzanne; Assmann, Susan F et al. (2012) Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 120:748-60
Slichter, Sherrill J; Kaufman, Richard M; Assmann, Susan F et al. (2010) Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 362:600-13
Steiner, M E; Assmann, S F; Levy, J H et al. (2010) Addressing the question of the effect of RBC storage on clinical outcomes: the Red Cell Storage Duration Study (RECESS) (Section 7). Transfus Apher Sci 43:107-16
Slichter, Sherrill J (2006) Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. J Clin Apher 21:78-84